Table 4.
Correlations between different APP‐derived peptides across clinical groups.
| Aβ1‐42 | Aβ1‐40 | Aβ1‐38 | |
|---|---|---|---|
| Alzheimer’s disease | |||
| sAPPβ | 0.29 (0.04–0.52)b | 0.39 (0.14–0.59) | 0.37 (0.14–0.58) |
| Aβ1‐42 | – | 0.70 (0.56–0.81) | 0.59 (0.40–0.73) b |
| Aβ1‐40 | – | – | 0.82 (0.73–0.89) |
| FTLD‐related syndromes | |||
| sAPPβ | 0.60 (0.38–0.77) a | 0.58 (0.35–0.73) | 0.60 (0.42–0.64) |
| Aβ1‐42 | – | 0.84 (0.77–0.90) c | 0.89 (0.84–0.93) ac |
| Aβ1‐40 | – | – | 0.88 (0.82–0.92) |
| Healthy control | |||
| sAPPβ | 0.42 (0.18–0.63) | 0.47 (0.25–0.65) | 0.57 (0.37–0.72) |
| Aβ1‐42 | – | 0.60 (0.40–0.76) b | 0.62 (0.40–0.80) b |
| Aβ1‐40 | – | – | 0.89 (0.82–0.94) |
Correlation between Aβ1‐42, Aβ1‐40, and Aβ1‐38 and sAPPβ in (A) AD group, (B) FTLD‐related syndromes group, and (C) healthy control group. Results are shown as Pearson’s correlation coefficient (95% confidence interval). 95% confidence intervals were calculated by means of bias‐corrected accelerated bootstrapping (1000 samples). Moderate‐to‐high correlations (r > 0.5) are in bold. The correlations that are significantly different between groups are underlined; a: different from the AD group; b: different from the FTLD‐related syndromes group; c: different from the healthy control group. APP, amyloid precursor protein; Aβ, amyloid β; FTLD, frontotemporal lobar degeneration; sAPPβ, soluble β fragment of amyloid precursor protein.